Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (179) 179
science & technology (144) 144
life sciences & biomedicine (142) 142
male (136) 136
female (124) 124
middle aged (123) 123
aged (110) 110
adult (107) 107
oncology (104) 104
biological and medical sciences (94) 94
medical sciences (94) 94
tumors (54) 54
abridged index medicus (50) 50
chemotherapy (48) 48
cancer (47) 47
aged, 80 and over (46) 46
combined modality therapy (46) 46
treatment outcome (43) 43
antineoplastic combined chemotherapy protocols - therapeutic use (42) 42
otorhinolaryngology (42) 42
head and neck neoplasms - drug therapy (41) 41
carcinoma, squamous cell - drug therapy (39) 39
antineoplastic agents (37) 37
pharmacology. drug treatments (37) 37
neoplasm staging (36) 36
surgery (36) 36
radiotherapy (31) 31
head and neck neoplasms - radiotherapy (30) 30
otorhinolaryngology. stomatology (30) 30
prognosis (30) 30
disease-free survival (29) 29
head and neck neoplasms - pathology (28) 28
survival rate (28) 28
head and neck neoplasms - therapy (27) 27
care and treatment (26) 26
carcinoma, squamous cell - pathology (24) 24
retrospective studies (24) 24
antineoplastic agents - therapeutic use (23) 23
antineoplastic combined chemotherapy protocols - adverse effects (23) 23
survival analysis (22) 22
adolescent (20) 20
head and neck cancer (20) 20
head and neck neoplasms - mortality (20) 20
squamous cell carcinoma (20) 20
carcinoma, squamous cell - mortality (19) 19
carcinoma, squamous cell - radiotherapy (19) 19
cisplatin - administration & dosage (19) 19
quality of life (19) 19
radiation (19) 19
follow-up studies (18) 18
fluorouracil - administration & dosage (17) 17
paclitaxel - administration & dosage (15) 15
carcinoma, squamous cell - therapy (14) 14
lung neoplasms - drug therapy (14) 14
patients (14) 14
radiotherapy dosage (14) 14
research (14) 14
cetuximab (13) 13
neck (13) 13
prospective studies (13) 13
radiology, nuclear medicine & medical imaging (13) 13
carcinoma, non-small-cell lung - drug therapy (12) 12
clinical trials (12) 12
drug administration schedule (12) 12
neoplasms (12) 12
radiotherapy, adjuvant (12) 12
remission induction (12) 12
antibodies, monoclonal, humanized (11) 11
carboplatin - administration & dosage (11) 11
carcinoma (11) 11
immunohistochemistry (11) 11
metastasis (11) 11
neoplasms - drug therapy (11) 11
chemotherapy, adjuvant (10) 10
dose-response relationship, drug (10) 10
head (10) 10
hematology, oncology and palliative medicine (10) 10
maximum tolerated dose (10) 10
oropharyngeal neoplasms - radiotherapy (10) 10
pathology (10) 10
radiation therapy (10) 10
radiology (10) 10
salivary gland neoplasms - pathology (10) 10
therapy (10) 10
toxicity (10) 10
young adult (10) 10
head and neck neoplasms - surgery (9) 9
health aspects (9) 9
hydroxyurea - administration & dosage (9) 9
lung neoplasms - mortality (9) 9
radiology and nuclear medicine (9) 9
radiotherapy, intensity-modulated - methods (9) 9
survival (9) 9
time factors (9) 9
antibodies, monoclonal - therapeutic use (8) 8
disease progression (8) 8
drug therapy (8) 8
infusions, intravenous (8) 8
kaplan-meier estimate (8) 8
mutation (8) 8
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Head and neck cancer
: a multidisciplinary approach
by Harrison, Louis B., editor and Kies, Merrill S., editor and Sessions, Roy B., editor
2014, Fourth edition., ISBN 1451144873, xxi, 908 pages
diagnosis | therapy | Head and Neck Neoplasms | Head | Neck | Cancer
Book
Details down arrow
2. Full Text Does induction chemotherapy advance the multimodal treatment of locally advanced esthesioneuroblastoma and sinonasal tumor with neuroendocrine differentiation?
by Kies, Merrill
Cancer Research, Statistics, and Treatment, ISSN 2590-3233, 7/2020, Volume 3, Issue 3, pp. 650 - 651
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Phase II Study of Low-Dose Paclitaxel and Cisplatin in Combination With Split-Course Concomitant Twice-Daily Reirradiation in Recurrent Squamous Cell Carcinoma of the Head and Neck: Results of Radiation Therapy Oncology Group Protocol 9911
by Corey J. Langer and Jonathan Harris and Eric M. Horwitz and Nicos Nicolaou and Merrill Kies and Walter Curran and Stuart Wong and Kian Ang
Journal of clinical oncology, ISSN 0732-183X, 10/2007, Volume 25, Issue 30, pp. 4800 - 4805
Life Sciences & Biomedicine | Oncology | Science & Technology | Biological and medical sciences | Medical sciences | Otorhinolaryngology. Stomatology | Otorhinolaryngology (head neck, general aspects and miscellaneous) | Tumors | Neoplasm Recurrence, Local - radiotherapy | Humans | Middle Aged | Head and Neck Neoplasms - drug therapy | Carcinoma, Squamous Cell - therapy | Neoplasm Recurrence, Local - drug therapy | Male | Survival Rate | Combined Modality Therapy | Neoplasm Recurrence, Local - surgery | Cisplatin - administration & dosage | Head and Neck Neoplasms - radiotherapy | Maximum Tolerated Dose | Carcinoma, Squamous Cell - mortality | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged, 80 and over | Adult | Dose Fractionation | Female | Aged | Paclitaxel - administration & dosage | Head and Neck Neoplasms - surgery | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study
by Ezra E.W. Cohen and Lee S. Rosen and Everett E. Vokes and Merrill S. Kies and Arlene A. Forastiere and Francis P. Worden and Madeleine A. Kane and Eric Sherman and Sinil Kim and Paul Bycott and Michael Tortorici and David R. Shalinsky and Katherine F. Liau and Roger B. Cohen
Journal of clinical oncology, ISSN 0732-183X, 10/2008, Volume 26, Issue 29, pp. 4708 - 4713
Biological and medical sciences | Chemotherapy | Medical sciences | Antineoplastic agents | Pharmacology. Drug treatments | Tumors | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Thyroid Neoplasms - drug therapy | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Adult | Female | Aged | Imidazoles - therapeutic use | Indazoles - therapeutic use | Thyroid Neoplasms - pathology | Index Medicus | Head and Neck Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
by Bonner, James A and Harari, Paul M and Giralt, Jordi and Azarnia, Nozar and Shin, Dong M and Cohen, Roger B and Jones, Christopher U and Sur, Ranjan and Raben, David and Jassem, Jacek and Ove, Roger and Kies, Merrill S and Baselga, Jose and Youssoufian, Hagop and Amellal, Nadia and Rowinsky, Eric K and Ang, K. Kian
The New England journal of medicine, ISSN 0028-4793, 02/2006, Volume 354, Issue 6, pp. 567 - 578
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Biological and medical sciences | General aspects | Medical sciences | Otorhinolaryngology. Stomatology | Otorhinolaryngology (head neck, general aspects and miscellaneous) | Tumors | Receptor, Epidermal Growth Factor - immunology | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Head and Neck Neoplasms - drug therapy | Antibodies, Monoclonal - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Combined Modality Therapy | Carcinoma, Squamous Cell - radiotherapy | Disease Progression | Antibodies, Monoclonal, Humanized | Head and Neck Neoplasms - radiotherapy | Carcinoma, Squamous Cell - drug therapy | Carcinoma, Squamous Cell - mortality | Antineoplastic Agents - adverse effects | Survival Analysis | Aged, 80 and over | Adult | Female | Aged | Head and Neck Neoplasms - mortality | Cetuximab | Squamous cell carcinoma | Care and treatment | Radiotherapy | Health aspects | Therapy | Head | Neck | Radiation | Skin cancer | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Predicting two‐year longitudinal MD Anderson Dysphagia Inventory outcomes after intensity modulated radiotherapy for locoregionally advanced oropharyngeal carcinoma
by Goepfert, Ryan P and Lewin, Jan S and Barrow, Martha P and Fuller, C. David and Lai, Stephen Y and Song, Juhee and Hobbs, Brian P and Gunn, G. Brandon and Beadle, Beth M and Rosenthal, David I and Garden, Adam S and Kies, Merrill S and Papadimitrakopoulou, Vali A and Schwartz, David L and Hutcheson, Katherine A
The Laryngoscope, ISSN 0023-852X, 04/2017, Volume 127, Issue 4, pp. 842 - 848
dysphagia | intensity modulated radiotherapy | MD Anderson Dysphagia Inventory | oropharyngeal carcinoma | patient‐reported outcomes | patient-reported outcomes | Otorhinolaryngology | Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | Multivariate Analysis | Predictive Value of Tests | Prognosis | United States | Humans | Middle Aged | Oropharyngeal Neoplasms - mortality | Carcinoma - mortality | Male | Oropharyngeal Neoplasms - pathology | Radiotherapy, Intensity-Modulated - adverse effects | Time Factors | Neoplasm Invasiveness - pathology | Adult | Deglutition Disorders - etiology | Female | Retrospective Studies | Carcinoma - pathology | Deglutition Disorders - physiopathology | Databases, Factual | Risk Assessment | Radiotherapy, Intensity-Modulated - methods | Self Report | Deglutition Disorders - epidemiology | Oropharyngeal Neoplasms - radiotherapy | Survival Rate | Carcinoma - radiotherapy | Cancer Care Facilities | Disease-Free Survival | Aged | Neoplasm Staging | Longitudinal Studies | Medical research | Carcinoma | Medicine, Experimental | Radiotherapy | Deglutition disorders | Cancer | Dysphagia | Radiation therapy | Patients | Tumors | Index Medicus | MDADI | IMRT
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: A single‐arm phase 2 clinical trial
by Gold, Kathryn A and Kies, Merrill S and William, William N and Johnson, Faye M and Lee, J. Jack and Glisson, Bonnie S
Cancer, ISSN 0008-543X, 05/2018, Volume 124, Issue 10, pp. 2169 - 2173
skin cancer | anti‐neoplastic agents | erlotinib | epidermal growth factor receptor | squamous cell carcinoma | anti-neoplastic agents | Life Sciences & Biomedicine | Oncology | Science & Technology | Clinical trials | Squamous cell carcinoma | Dosage and administration | Research | Erlotinib | Drug therapy | Tyrosine | Therapy | Epidermal growth factor receptors | Toxicity | Malignancy | Metastasis | Disease control | Patients | Survival | Metastases | Confidence intervals | Epidermal growth factor | Response rates | Growth factors | Protein-tyrosine kinase | Cancer | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Phase I Trial of the Oral Antiangiogenesis Agent AG-013736 in Patients With Advanced Solid Tumors: Pharmacokinetic and Clinical Results
by Hope S. Rugo and Roy S. Herbst and Glenn Liu and John W. Park and Merrill S. Kies and Heidi M. Steinfeldt and Yazdi K. Pithavala and Steven D. Reich and James L. Freddo and George Wilding
Journal of clinical oncology, ISSN 0732-183X, 08/2005, Volume 23, Issue 24, pp. 5474 - 5483
Biological and medical sciences | Medical sciences | Tumors | Drug Administration Schedule | Administration, Oral | Area Under Curve | Humans | Middle Aged | Male | Treatment Outcome | Angiogenesis Inhibitors - pharmacokinetics | Indazoles - administration & dosage | Neoplasms - drug therapy | Angiogenesis Inhibitors - administration & dosage | Maximum Tolerated Dose | Drug Interactions | Imidazoles | Indazoles - pharmacokinetics | Neoplasms - blood | Neovascularization, Pathologic - drug therapy | Adult | Female | Aged | Indazoles - adverse effects | Angiogenesis Inhibitors - adverse effects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Outcomes and patterns of care of patients with locally advanced oropharyngeal carcinoma treated in the early 21st century
by Garden, Adam S and Kies, Merrill S and Morrison, William H and Weber, Randal S and Frank, Steven J and Glisson, Bonnie S and Gunn, Gary B and Beadle, Beth M and Ang, K Kian and Rosenthal, David I and Sturgis, Erich M
Radiation oncology (London, England), ISSN 1748-717X, 01/2013, Volume 8, Issue 1, pp. 21 - 21
IMRT | Squamous cell | Chemoradiation | Oropharyngeal cancer | Radiation | Oncology | Life Sciences & Biomedicine | Radiology, Nuclear Medicine & Medical Imaging | Science & Technology | Oropharyngeal Neoplasms - therapy | Prognosis | Follow-Up Studies | History, 21st Century | Humans | Middle Aged | Oropharyngeal Neoplasms - mortality | Male | Oropharyngeal Neoplasms - pathology | Neoplasm Recurrence, Local - mortality | Neoplasm Recurrence, Local - pathology | Clinical Trials, Phase III as Topic | Carcinoma, Squamous Cell - mortality | Aged, 80 and over | Adult | Female | Neoplasm Recurrence, Local - therapy | Carcinoma, Squamous Cell - therapy | Survival Rate | Treatment Outcome | Combined Modality Therapy | Disease-Free Survival | Carcinoma, Squamous Cell - secondary | Aged | Neoplasm Staging | Clinical Trials, Phase II as Topic | Chemotherapy | Human papillomavirus | Hospitals | Colleges & universities | FDA approval | Family medical history | Head & neck cancer | Multivariate analysis | Epidemiology | Cancer therapies | Patients | Disease control | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Phase II Multicenter Study of the Epidermal Growth Factor Receptor Antibody Cetuximab and Cisplatin for Recurrent and Refractory Squamous Cell Carcinoma of the Head and Neck
by Roy S. Herbst and Matthew Arquette and Dong M. Shin and Karel Dicke and Everett E. Vokes and Nozar Azarnia and Waun Ki Hong and Merrill S. Kies
Journal of clinical oncology, ISSN 0732-183X, 08/2005, Volume 23, Issue 24, pp. 5578 - 5587
Life Sciences & Biomedicine | Oncology | Science & Technology | Biological and medical sciences | Medical sciences | Otorhinolaryngology. Stomatology | Otorhinolaryngology (head neck, general aspects and miscellaneous) | Tumors | Carcinoma, Squamous Cell - pathology | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Male | Cisplatin - administration & dosage | Neoplasm Recurrence, Local - pathology | Antibodies, Monoclonal, Humanized | Fluorouracil - administration & dosage | Aged, 80 and over | Adult | Female | Cetuximab | Paclitaxel - administration & dosage | Drug Administration Schedule | Head and Neck Neoplasms - drug therapy | Logistic Models | Treatment Outcome | Disease Progression | Head and Neck Neoplasms - pathology | Carcinoma, Squamous Cell - drug therapy | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Induction Chemotherapy and Cetuximab for Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Results From a Phase II Prospective Trial
by Merrill S. Kies and Floyd Christopher Holsinger and J. Jack Lee and William N. William, Jr and Bonnie S. Glisson and Heather Y. Lin and Jan S. Lewin and Lawrence E. Ginsberg and Katharine A. Gillaspy and Erminia Massarelli and Lauren Byers and Scott M. Lippman and Waun K. Hong and Adel K. El-Naggar and Adam S. Garden and Vassiliki Papadimitrakopoulou
Journal of clinical oncology, ISSN 0732-183X, 01/2010, Volume 28, Issue 1, pp. 8 - 14
Life Sciences & Biomedicine | Oncology | Science & Technology | Biological and medical sciences | Medical sciences | Otorhinolaryngology. Stomatology | Otorhinolaryngology (head neck, general aspects and miscellaneous) | Tumors | Prospective Studies | Humans | Middle Aged | Head and Neck Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carboplatin - administration & dosage | Male | Receptor, Epidermal Growth Factor - analysis | Papillomaviridae - isolation & purification | Antibodies, Monoclonal, Humanized | Carcinoma, Squamous Cell - drug therapy | Carcinoma, Squamous Cell - mortality | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adult | Female | Aged | Head and Neck Neoplasms - mortality | Cetuximab | Paclitaxel - administration & dosage | Index Medicus | Original Reports | Hnc5
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Randomized Phase III Trial of Induction Chemotherapy With Docetaxel, Cisplatin, and Fluorouracil Followed by Surgery Versus Up-Front Surgery in Locally Advanced Resectable Oral Squamous Cell Carcinoma
by Lai-ping Zhong and Chen-ping Zhang and Guo-xin Ren and Wei Guo and William N. William Jr and Jian Sun and Han-guang Zhu and Wen-yong Tu and Jiang Li and Yi-li Cai and Li-zhen Wang and Xin-dong Fan and Zhong-he Wang and Yong-jie Hu and Tong Ji and Wen-jun Yang and Wei-min Ye and Jun Li and Yue He and Yan-an Wang and Li-qun Xu and Bo-song Wang and Merrill S. Kies and J. Jack Lee and Jeffrey N. Myers and Zhi-yuan Zhang
Journal of clinical oncology, ISSN 0732-183X, 02/2013, Volume 31, Issue 6, pp. 744 - 751
Life Sciences & Biomedicine | Oncology | Science & Technology | Biological and medical sciences | Medical sciences | Otorhinolaryngology. Stomatology | Upper respiratory tract, upper alimentary tract, paranasal sinuses, salivary glands: diseases, semeiology | Tumors | Mouth Neoplasms - drug therapy | Prospective Studies | Follow-Up Studies | Nausea - chemically induced | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carcinoma, Squamous Cell - surgery | Male | Radiotherapy - adverse effects | Cisplatin - administration & dosage | Fluorouracil - administration & dosage | Fluorouracil - adverse effects | Adult | Female | Mouth Neoplasms - radiotherapy | Taxoids - adverse effects | Hematologic Diseases - chemically induced | Docetaxel | Induction Chemotherapy - methods | Kaplan-Meier Estimate | Treatment Outcome | Combined Modality Therapy | Induction Chemotherapy - adverse effects | Taxoids - administration & dosage | Carcinoma, Squamous Cell - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mucositis - etiology | Mouth Neoplasms - surgery | Radiotherapy - methods | Cisplatin - adverse effects | Alopecia - chemically induced | Aged | Index Medicus | ORIGINAL REPORTS
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy
by Saintigny, Pierre and Mitani, Yoshitsugu and Pytynia, Kristen B and Ferrarotto, Renata and Roberts, Dianna B and Weber, Randal S and Kies, Merrill S and Maity, Sankar N and Lin, Sue‐Hwa and El‐Naggar, Adel K
Cancer, ISSN 0008-543X, 09/2018, Volume 124, Issue 18, pp. 3693 - 3705
phosphatase and tensin homolog (PTEN) loss | targeted therapy | salivary duct carcinoma | salivary gland carcinoma | phosphoinositide 3‐kinase (PI3K) pathway | phosphoinositide 3-kinase (PI3K) pathway | Life Sciences & Biomedicine | Oncology | Science & Technology | Therapy | Carcinoma | Homology | AKT protein | Malignancy | Kinases | Proteins | Phosphatidylinositol | Signal transduction | Alterations | Epidermal growth factor | Tumorigenesis | Catalysis | Growth factors | Tensin | Abnormalities | Patients | ErbB-2 protein | 1-Phosphatidylinositol 3-kinase | Signaling | Inhibitors | Biomarkers | Solid tumors | Mutation | PTEN protein | Cancer | Tumors | Index Medicus | Abridged Index Medicus | PI3K pathway | Salivary duct carcinoma | Targeted therapy | PTEN loss | Salivary gland carcinoma
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights